NYSE:BVS Bioventus (BVS) Stock Price, News & Analysis → Like Tiny Crypto Retirement Funds (From Crypto 101 Media) (Ad) Free BVS Stock Alerts $5.49 +0.04 (+0.73%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$5.39▼$5.5450-Day Range$4.33▼$5.6052-Week Range$0.80▼$6.08Volume130,727 shsAverage Volume146,380 shsMarket Capitalization$432.34 millionP/E RatioN/ADividend YieldN/APrice Target$7.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get Bioventus alerts: Email Address Bioventus MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside39.6% Upside$7.67 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.09Based on 9 Articles This WeekInsider TradingN/AProj. Earnings Growth218.75%From $0.16 to $0.51 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.31 out of 5 starsMedical Sector605th out of 947 stocksSurgical & Medical Instruments Industry66th out of 99 stocks 3.5 Analyst's Opinion Consensus RatingBioventus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.67, Bioventus has a forecasted upside of 39.6% from its current price of $5.49.Amount of Analyst CoverageBioventus has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for BVS. Previous Next 0.0 Dividend Strength Dividend YieldBioventus does not currently pay a dividend.Dividend GrowthBioventus does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BVS. Previous Next 2.8 News and Social Media Coverage News SentimentBioventus has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Bioventus this week, compared to 1 article on an average week.Search Interest8 people have searched for BVS on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows4 people have added Bioventus to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bioventus insiders have not sold or bought any company stock.Percentage Held by Insiders29.10% of the stock of Bioventus is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.65% of the stock of Bioventus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Bioventus are expected to grow by 218.75% in the coming year, from $0.16 to $0.51 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bioventus is -2.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bioventus is -2.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioventus has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingAI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… ]click here to watch a free presentation where I reveal all the details of this lucrative opportunit About Bioventus Stock (NYSE:BVS)Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices used for precise bone sculpting, removing tumors, and tissue debridement. The company's restorative therapies include a bone healing system; skin allografts; and products that are used to support healing of wounds, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.Read More BVS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BVS Stock News HeadlinesMarch 13, 2024 | bizjournals.comDurham public company resets priorities under new CEOMarch 13, 2024 | finance.yahoo.comBioventus Inc. (NASDAQ:BVS) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | The Bull Report (Ad)The AI Bottleneck No One is Talking AboutRenewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever.March 12, 2024 | markets.businessinsider.comWhat Wall Street expects from Repro Medical System's earningsMarch 12, 2024 | msn.comBioventus Non-GAAP EPS of $0.07 beats by $0.05, revenue of $135.42M beats by $11.46MMarch 12, 2024 | finance.yahoo.comBioventus Inc (BVS) Reports Growth in Q4 Sales and Adjusted EBITDA, Provides Optimistic 2024 ...March 12, 2024 | globenewswire.comBioventus Announces Fourth Quarter and Full Year 2023 Financial ResultsMarch 12, 2024 | nz.finance.yahoo.comBioventus Inc. (BVS) stock price, news, quote & history – Yahoo FinanceMarch 19, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 11, 2024 | benzinga.comA Preview Of Bioventus's EarningsMarch 10, 2024 | americanbankingnews.comHead to Head Analysis: Pro-Dex (NASDAQ:PDEX) vs. Bioventus (NYSE:BVS)March 10, 2024 | americanbankingnews.comBioventus (BVS) Set to Announce Quarterly Earnings on TuesdayMarch 10, 2024 | americanbankingnews.comComparing TELA Bio (NASDAQ:TELA) & Bioventus (NYSE:BVS)March 4, 2024 | globenewswire.comBioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024February 15, 2024 | wsj.comBioventus Inc. Cl AJanuary 24, 2024 | seekingalpha.comBioventus: Bullish On Path To ProfitabilityJanuary 19, 2024 | finanznachrichten.deBioventus, Inc.: Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational FlexibilityJanuary 12, 2024 | finance.yahoo.comBioventus Announces Inducement Equity to President and Chief Executive Officer Robert ClaypooleDecember 27, 2023 | businesswire.comBIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmDecember 21, 2023 | benzinga.comBioventus Stock (NASDAQ:BVS) Dividends: History, Yield and DatesDecember 20, 2023 | bizjournals.comDurham public company names new CEO at critical junctureDecember 19, 2023 | finance.yahoo.comBioventus Names Robert Claypoole as President and Chief Executive OfficerDecember 16, 2023 | msn.comBioventus Inc - (BVS) Price Target Increased by 34.58% to 6.63December 8, 2023 | msn.comCanaccord Genuity Upgrades Bioventus Inc - (BVS)November 27, 2023 | msn.comBioventus Inc - (BVS) Price Target Increased by 7.33% to 4.93November 14, 2023 | morningstar.comBioventus Inc Class ANovember 12, 2023 | finance.yahoo.comBioventus Inc. (NASDAQ:BVS) Q3 2023 Earnings Call TranscriptSee More Headlines Receive BVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioventus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today3/18/2024Next Earnings (Estimated)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNYSE:BVS CUSIPN/A CIK1665988 Webwww.bioventus.com Phone919-474-6700FaxN/AEmployees1,120Year FoundedN/APrice Target and Rating Average Stock Price Target$7.67 High Stock Price Target$9.00 Low Stock Price Target$7.00 Potential Upside/Downside+39.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.52) Trailing P/E RatioN/A Forward P/E Ratio34.31 P/E GrowthN/ANet Income$-158,700,000.00 Net Margins-30.49% Pretax Margin-23.64% Return on Equity2.25% Return on Assets0.62% Debt Debt-to-Equity Ratio1.66 Current Ratio1.53 Quick Ratio0.94 Sales & Book Value Annual Sales$512.34 million Price / Sales0.84 Cash Flow$0.84 per share Price / Cash Flow6.54 Book Value$4.37 per share Price / Book1.26Miscellaneous Outstanding Shares78,750,000Free Float55,836,000Market Cap$432.34 million OptionableNot Optionable Beta0.48 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Mark L. Singleton (Age 54)Senior VP & CFO Comp: $444.12kMr. Robert ClaypoolePresident, CEO & DirectorMr. Mike Crowe B.S.M.B.A., Senior Vice President of OperationsMr. David CrawfordVice President of Investor Relations & TreasurerMr. Anthony D'Adamio (Age 63)Senior VP, General Counsel & Corporate Secretary Comp: $618.29kMs. Katrina J. Church J.D. (Age 62)Chief Compliance Officer Ms. Helen LeupoldSenior VP & Chief Human Resources OfficerMr. Larry ChenManaging Director of China & Asia PacificMore ExecutivesKey CompetitorsAVITA MedicalNASDAQ:RCELCVRxNASDAQ:CVRXSurmodicsNASDAQ:SRDXBeauty HealthNASDAQ:SKINCerusNASDAQ:CERSView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 17,420 shares on 3/11/2024Ownership: 1.547%Goldman Sachs Group Inc.Bought 34,386 shares on 3/1/2024Ownership: 0.044%Vanguard Group Inc.Bought 17,420 shares on 2/15/2024Ownership: 1.547%Occudo Quantitative Strategies LPBought 23,128 shares on 2/15/2024Ownership: 0.029%Citadel Advisors LLCSold 2,100 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions BVS Stock Analysis - Frequently Asked Questions Should I buy or sell Bioventus stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bioventus in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BVS shares. View BVS analyst ratings or view top-rated stocks. What is Bioventus' stock price target for 2024? 3 brokers have issued 12-month target prices for Bioventus' stock. Their BVS share price targets range from $7.00 to $9.00. On average, they predict the company's stock price to reach $7.67 in the next twelve months. This suggests a possible upside of 39.6% from the stock's current price. View analysts price targets for BVS or view top-rated stocks among Wall Street analysts. How have BVS shares performed in 2024? Bioventus' stock was trading at $5.27 at the beginning of the year. Since then, BVS shares have increased by 4.2% and is now trading at $5.49. View the best growth stocks for 2024 here. When is Bioventus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our BVS earnings forecast. How were Bioventus' earnings last quarter? Bioventus Inc. (NYSE:BVS) released its earnings results on Monday, November, 8th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.14 by $0.11. The business earned $108.89 million during the quarter, compared to the consensus estimate of $105.48 million. Bioventus had a positive trailing twelve-month return on equity of 2.25% and a negative net margin of 30.49%. What guidance has Bioventus issued on next quarter's earnings? Bioventus issued an update on its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided EPS guidance of 0.120-0.200 for the period, compared to the consensus EPS estimate of 0.330. The company issued revenue guidance of $520.0 million-$535.0 million, compared to the consensus revenue estimate of $517.8 million. When did Bioventus IPO? (BVS) raised $126 million in an IPO on Thursday, February 11th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity acted as the underwriters for the IPO. Who are Bioventus' major shareholders? Bioventus' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Nantahala Capital Management LLC (7.59%), Vanguard Group Inc. (1.55%), Vanguard Group Inc. (1.55%), Kent Lake Capital LLC (0.68%), Charles Schwab Investment Management Inc. (0.23%) and Stephens Inc. AR (0.18%). Insiders that own company stock include Anthony D'adamio, Anthony P Bihl III, John A Bartholdson, John Nosenzo, Juniper Investment Company, Ll, Katrina J Church, Kenneth Michael Reali, Mark Leonard Singleton and William A Hawkins. View institutional ownership trends. How do I buy shares of Bioventus? Shares of BVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:BVS) was last updated on 3/19/2024 by MarketBeat.com Staff From Our Partners8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & CompanyStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioventus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.